{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Carcinoma&page=9",
    "query": {
      "condition": "Metastatic Colorectal Carcinoma",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 1154,
    "total_pages": 116,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Carcinoma&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Carcinoma&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T18:44:54.547Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03602885",
      "title": "EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer",
        "Unresectable Pancreatic Cancer",
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Usual chemotherapy education (CE)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Chemotherapy education intervention (CEI)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2018-09-01",
      "completion_date": "2020-11-27",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-10-14T18:44:54.547Z",
      "location_count": 5,
      "location_summary": "Tampa, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 1 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03602885"
    },
    {
      "nct_id": "NCT07130903",
      "title": "Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Fruquintinib",
          "type": "DRUG"
        },
        {
          "name": "TheraBionic P1",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2025-09-10",
      "completion_date": "2030-04-17",
      "has_results": false,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-14T18:44:54.547Z",
      "location_count": 9,
      "location_summary": "Bay City, Michigan • Clarkston, Michigan • Detroit, Michigan + 6 more",
      "locations": [
        {
          "city": "Bay City",
          "state": "Michigan"
        },
        {
          "city": "Clarkston",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Flint",
          "state": "Michigan"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07130903"
    },
    {
      "nct_id": "NCT00496860",
      "title": "Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Progressive Metastatic Malignancies"
      ],
      "interventions": [
        {
          "name": "ALT-801",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Altor BioScience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2007-05",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-07-22",
      "last_synced_at": "2026-10-14T18:44:54.547Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Orlando, Florida • Tampa, Florida + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00496860"
    },
    {
      "nct_id": "NCT04579380",
      "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uterine Neoplasms",
        "Uterine Cervical Neoplasms",
        "Biliary Tract Neoplasms",
        "Urologic Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "HER2 Mutations Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "tucatinib",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 217,
      "start_date": "2021-01-11",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-14T18:44:54.547Z",
      "location_count": 76,
      "location_summary": "Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04579380"
    },
    {
      "nct_id": "NCT01960023",
      "title": "Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Neratinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NSABP Foundation Inc",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2013-10",
      "completion_date": "2016-07-13",
      "has_results": false,
      "last_update_posted_date": "2021-10-27",
      "last_synced_at": "2026-10-14T18:44:54.547Z",
      "location_count": 12,
      "location_summary": "Gainesville, Florida • Orlando, Florida • Boise, Idaho + 7 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01960023"
    },
    {
      "nct_id": "NCT00931840",
      "title": "A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "EZN-2208, Cetuximab and Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enzon Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2009-06",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2011-09-20",
      "last_synced_at": "2026-10-14T18:44:54.547Z",
      "location_count": 35,
      "location_summary": "Tucson, Arizona • Alhambra, California • Bakersfield, California + 30 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00931840"
    },
    {
      "nct_id": "NCT01571024",
      "title": "BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Metastatic Colorectal Cancer",
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "BKM120",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2012-05",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-10-14T18:44:54.547Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01571024"
    },
    {
      "nct_id": "NCT00003103",
      "title": "Chemotherapy in Treating Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Lung Cancer",
        "Ovarian Cancer",
        "Prostate Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "oblimersen sodium",
          "type": "BIOLOGICAL"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "1997-08",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2013-07-03",
      "last_synced_at": "2026-10-14T18:44:54.547Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003103"
    },
    {
      "nct_id": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acinar Cell Carcinoma",
        "Adenoid Cystic Carcinoma",
        "Adrenal Cortical Carcinoma",
        "Adrenal Gland Pheochromocytoma",
        "Anal Canal Neuroendocrine Carcinoma",
        "Anal Canal Undifferentiated Carcinoma",
        "Angiosarcoma",
        "Apocrine Neoplasm",
        "Appendix Mucinous Adenocarcinoma",
        "Bartholin Gland Transitional Cell Carcinoma",
        "Basal Cell Carcinoma",
        "Bladder Adenocarcinoma",
        "Breast Metaplastic Carcinoma",
        "Cervical Adenocarcinoma",
        "Cholangiocarcinoma",
        "Chordoma",
        "Colorectal Squamous Cell Carcinoma",
        "Desmoid Fibromatosis",
        "Endometrial Transitional Cell Carcinoma",
        "Endometrioid Adenocarcinoma",
        "Esophageal Neuroendocrine Carcinoma",
        "Esophageal Undifferentiated Carcinoma",
        "Extrahepatic Bile Duct Carcinoma",
        "Extramammary Paget Disease",
        "Fallopian Tube Adenocarcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Fibromyxoid Tumor",
        "Gallbladder Carcinoma",
        "Gastric Neuroendocrine Carcinoma",
        "Gastric Squamous Cell Carcinoma",
        "Gastric Undifferentiated Carcinoma",
        "Gastrointestinal Stromal Tumor",
        "Gestational Trophoblastic Tumor",
        "Giant Cell Carcinoma",
        "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type",
        "Intestinal Neuroendocrine Carcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Lung Neuroendocrine Tumor",
        "Lung Sarcomatoid Carcinoma",
        "Major Salivary Gland Carcinoma",
        "Malignant Neoplasm of Unknown Primary",
        "Malignant Odontogenic Neoplasm",
        "Malignant Peripheral Nerve Sheath Tumor",
        "Malignant Solid Neoplasm",
        "Malignant Testicular Sex Cord-Stromal Tumor",
        "Metastatic Pituitary Neuroendocrine Tumor",
        "Minimally Invasive Lung Adenocarcinoma",
        "Mixed Mesodermal (Mullerian) Tumor",
        "Mucinous Adenocarcinoma",
        "Mucinous Cystadenocarcinoma",
        "Nasal Cavity Adenocarcinoma",
        "Nasal Cavity Carcinoma",
        "Nasopharyngeal Carcinoma",
        "Nasopharyngeal Low Grade Papillary Adenocarcinoma",
        "Nasopharyngeal Undifferentiated Carcinoma",
        "Oral Cavity Carcinoma",
        "Oropharyngeal Undifferentiated Carcinoma",
        "Ovarian Adenocarcinoma",
        "Ovarian Germ Cell Tumor",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Squamous Cell Carcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Pancreatic Acinar Cell Carcinoma",
        "Pancreatic Neuroendocrine Carcinoma",
        "Paraganglioma",
        "Paranasal Sinus Adenocarcinoma",
        "Paranasal Sinus Carcinoma",
        "Parathyroid Gland Carcinoma",
        "PEComa",
        "Penile Squamous Cell Carcinoma",
        "Peritoneal Mesothelial Neoplasm",
        "Placental Choriocarcinoma",
        "Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Pseudomyxoma Peritonei",
        "Rare Disorder",
        "Scrotal Squamous Cell Carcinoma",
        "Seminal Vesicle Adenocarcinoma",
        "Seminoma",
        "Serous Cystadenocarcinoma",
        "Small Intestinal Adenocarcinoma",
        "Small Intestinal Squamous Cell Carcinoma",
        "Spindle Cell Neoplasm",
        "Teratoma With Somatic-Type Malignancy",
        "Testicular Non-Seminomatous Germ Cell Tumor",
        "Thyroid Gland Carcinoma",
        "Tracheal Carcinoma",
        "Transitional Cell Carcinoma",
        "Ureter Adenocarcinoma",
        "Ureter Squamous Cell Carcinoma",
        "Urethral Adenocarcinoma",
        "Urethral Squamous Cell Carcinoma",
        "Vaginal Adenocarcinoma",
        "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified",
        "Vulvar Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 798,
      "start_date": "2017-01-30",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-10-14T18:44:54.547Z",
      "location_count": 1006,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834013"
    },
    {
      "nct_id": "NCT00216424",
      "title": "Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Capecitabine (Xeloda)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "James A. Haley Veterans Administration Hospital",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2005-02",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2007-11-12",
      "last_synced_at": "2026-10-14T18:44:54.547Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00216424"
    }
  ]
}